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Background: Inﬂammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC) is perceived to harbor signiﬁcant morbidity
but limited excess mortality, thought to be driven by colon cancer, compared with the general population. Recent studies suggest mortality rates seemh i g h e r
than previously understood, and there are emerging threats to mortality. Clinicians must be up to date and able to clearly convey the causes of mortality to
arm individual patients with information to meaningfully participate in decisions regarding IBD treatment and maintenance of health.
Methods: A MEDLINE search was conducted to capture all relevant articles. Keyword search included: “inﬂammatory bowel disease,”“ Crohn’s
disease,”“ ulcerative colitis,” and “mortality.”
Results: CD and UC have slightly different causes of mortality; however, malignancy and colorectal cancer–associated mortality remains controversial in
IBD. CD mortality seems to be driven by gastrointestinal disease, infection, and respiratory diseases. UC mortality was primarily attributable to gastroin-
testinal disease and infection. Clostridium difﬁcile infection is an emerging cause of mortality in IBD. UC and CD patients have a marked increase in risk of
thromboembolic disease. With advances in medical and surgical interventions, the exploration of treatment-associated mortality must continue to be evaluated.
Conclusions: Clinicians should be aware that conventional causes of death such as malignancy do not seem to be as signiﬁcant a burden as originally
perceived. However, emerging threats such as infection including C. difﬁcile are noteworthy. Although CD and UC share similar causes of death, there
seems to be some differences in cause-speciﬁc mortality.
(Inﬂamm Bowel Dis 2014;20:2483–2492)
Key Words: inﬂammatory bowel disease, Crohn’s disease, ulcerative colitis, mortality, cause-speciﬁc mortality
I
nﬂammatory bowel disease (IBD) refers to a common group of
chronic inﬂammatory diseases of the intestine that includes
Crohn’s disease (CD) and ulcerative colitis (UC).
1,2 Although early
literature suggests the overall excess mortality burden was negligi-
ble in UC and only marginally increased in CD compared with the
general population, emerging data are challenging earlier percep-
tions of IBD-associated mortality.
3–5 A large Danish population-
based IBD cohort and a recent meta-analysis are suggesting higher
excess mortality in both CD and UC then previously reported.
6,7
Traditionally, clinicians have ascribed much of the excess morality
in IBD to colorectal cancer (CRC); however, this may not be the
primary driver of mortality, and practitioners managing IBD must be
well versed in the landscape of threats that face patients today.
8–10
Addressing emerging threats such as venous thromboembolism
(VTE) and Clostridium difﬁcile infection (CDI),
8,9,11–19 navigating
patient concerns over cardiovascular disease,
20 and addressing
mortality concerns about new medical and surgical interventions
are critical for the patient-centered practitioner. In an era of per-
sonalized medicine, this review assists clinicians in updating and
summarizing the causes of mortality in IBD, to empower individ-
ual patients with information to participate in treatment decisions
and inform them of early clinical warning signs that require imme-
diate medical attention.
METHODS
The literature was reviewed using MEDLINE database
and included a keyword search using the terms: “inﬂammatory
bowel disease,”“ Crohn’sd i s e a s e , ”“ ulcerative colitis,” and
“mortality.” Discussion with content experts was conducted to
obtain key references. Furthermore, a recursive search of the
bibliographies of all relevant articles was completed. Where
possible, data have been presented as standardized mortality
ratio (SMR), standardized incidence ratio (SIR) with 95% con-
ﬁdence intervals (CI), relative risk (RR), hazard ratio (HR), or
adjusted odds ratio (aOR).
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Earlier meta-analyses have captured a summary estimate of
overall morality in CD and UC.
3,5 In CD, Duricova et al
3 con-
ducted a meta-analysis of 9 population-based studies totaling 5411
patients and found a signiﬁcantly increased pooled SMR of 1.39
(95% CI, 1.30–1.49). In the same vein, Jess et al
5 performed a UC
meta-analysis of 10 population-based inception cohorts totaling
10,443 patients with UC. They reported an overall pooled SMR
of 1.1 (95% CI, 0.9–1.2) suggesting that the overall risk of death in
UC was not different than the general population.
5 These divergent
rates of mortality in CD and UC continue to be observed in a more
recent population cohort. A Finish IBD cohort that included 1254
patients with UC and 550 patients with CD found an overall
morality SMR of 1.14 (95% CI, 0.84–1.49) in CD and an SMR
of 0.90 (95% CI, 0.77–1.06) in UC.
21 The rationale for the diver-
gence in IBD mortality is not completely clear; however, smoking
may have an important role because widely established smoking is
more common among patients with CD.
Emerging literature is beginning to challenge the pre-
viously reported magnitude of mortality in IBD and in particular
UC. Jess et al
6 assessed mortality of a Danish IBD population-
based cohort with 36,080 patients with UC and 15,361 patients
with CD over a 30-year time period. They found mortality was
increased by approximately 10% in patients with UC and 50%
among patients with CD compared with the general population.
Speciﬁcally, patients with UC had a HR of 1.25 (95% CI, 1.22–
1.28) and patients with CD had a HR of 1.73 (95% CI, 1.67–
1.80).
6 A recent meta-analysis by Bewtra et al,
7 which did not
include the large Danish IBD cohort, corroborated the modest
excess in mortality in patients with UC and reported an all-cause
mortality summary SMR of 1.19 (95% CI, 1.06–1.35). The all-
cause mortality summary SMR for patients with CD was re-
ported as 1.38 (95% CI, 1.23–1.55), which is in keeping with
the previous meta-analysis.
3,7 Given the large Danish IBD
population-based cohort that eclipses the previous meta-
analysis sample size in the context of robust longitudinal
follow-up, clinicians should be aware that the absolute mortality
rate in both UC and CD might be higher than originally per-
ceived. Although it is a modest increase in excess mortality, it
remains meaningfully important to patients. This is highlighted
by optics of mortality associated with diabetes, which also car-
ries with it a modest excess risk of morality with the SMR for
Type II diabetes 2.9 and Type I 1.8.
22
Earlier meta-analyses explored cause-speciﬁc mortality.
Speciﬁcally, CD mortality seemed to be driven by gastrointestinal
(GI) disease (SMR, 6.76; 95% CI, 4.37–10.45), which the authors
speculated might be explained by increased pancreatitis and
cholelithiasis-associated deaths, although these were not speciﬁ-
cally coded.
3 Furthermore, CD had increased risk of dying from
genitourinary diseases (SMR, 3.28; 95% CI, 1.69–6.35), which
the authors speculated was secondary to smoking-associated blad-
der cancer, although this was not speciﬁcally coded either.
3 Mor-
tality associated with respiratory diseases also potentially linked
to smoking such as chronic obstructive pulmonary disease (2.55;
95% CI, 1.19–5.47) and pulmonary malignancy (SMR, 2.72; 95%
CI, 1.35–5.45) were also increased in patients with CD.
3 The large
Danish IBD population-based cohort largely emphasizes similar
CD-related mortality-associated etiologies including GI disease
(HR, 5.71; 95% CI, 5.28–6.19) and respiratory diseases
(HR, 2.05; 95% CI, 1.86–2.27), although infection was notewor-
thy (HR, 3.23; 95% CI, 2.64–3.94).
6 However, UC mortality was
driven by pulmonary embolism (PE) (SMR, 4.0; 95% CI, 1.5–
8.7), nonalcoholic liver disease (SMR, 4.0; 95% CI, 2.5–6.5), and
pneumonia (SMR, 3.1; 95% CI, 2.0–4.6).
5 Interestingly, the
above Danish IBD cohort noted slight differences in causes of
mortality in patients with UC. UC mortality was driven by GI
disease (HR, 3.06; 95% CI, 2.88–3.25) and infection (HR, 2.21;
95% CI, 1.93–2.53), although PE was not speciﬁcally captured in
the coding process.
6 In the same study, Jess et al found that the
mortality greatly increased in the ﬁrst year after being diagnosed
with IBD (UC: HR, 2.43; 95% CI, 2.31–2.57 versus CD: HR,
3.69; 95% CI, 3.41–3.99). This was primarily driven by infection
(UC: HR, 9.17; 95% CI, 7.19–11.69; CD: HR, 10.19; 95% CI,
6.88–15.11) and GI disease (UC: HR, 13.27; 95% CI, 11.87–
14.82; CD: HR, 23.02; 95% CI, 19.69–26.92).
6 Overall mortality
fell dramatically during the 2- to 4-year period after diagnosis in
both UC (HR, 1.14; 95% CI, 1.09–1.19) and in CD (HR, 1.53;
95% CI, 1.43–1.63).
6 Interestingly, those diagnosed with UC in
childhood or adolescence had a 2.15-fold higher mortality than
those diagnosed at age 60 to 70 years.
6 In CD, mortality was 62%
higher in patients diagnosed at age 0 to 19 years versus those
diagnosed with CD at age of 60 to 79 years.
6
Ananthakrishnan et al
23 recently reported on the impact of
primary sclerosing cholangitis ( P S C )o nm o r t a l i t yi nI B D .I n
this multicenter cohort of 5506 patients with CD and 5522
patients with UC, 224 (2%) were diagnosed with IBD-PSC
and had higher mortality than those with IBD alone (OR,
3.51; 95% CI, 2.30–5.36).
23 Those with IBD-PSC also had
increased risk of cancers versus those with IBD alone (OR,
4.36; 95% CI, 2.99–6.37). This was primarily driven by excess
risk of cancer of the digestive tract (OR, 10.40; 95% CI, 6.86–
15.76), pancreatic (OR, 11.22; 95% CI, 4.11–30.62), CRC (OR,
5.00; 95% CI, 2.80–8.95), and cholangiocarcinoma (OR, 55.31;
95% CI, 22.20–137.80).
23
Cause-speciﬁc mortality data from meta-analyses must be
interpreted with caution given methodological limitations. Etiol-
ogies of cause-speciﬁc mortality frequently only had a few studies
to generate a pooled SMR. Accordingly, studies may be
underpowered, and generalizability to clinicians and clinical
practice may not be appropriate. This is particularly important
when cause-speciﬁc pooled SMRs are driven by a single
geographic-speciﬁc cohort. Additionally, it seems that heteroge-
neity was signiﬁcant in the UC meta-analysis (x2 ¼ 54, P ,
0.001) and not reported in the CD meta-analysis and thus one
must be cautious when interpreting subgroup cause-speciﬁc mor-
tality results.
3,5 See Table 1 for a summary of statements regarding
cause-speciﬁc mortality in IBD.
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Inﬂammation is thought to play a major role in the
development of thromboembolic phenomenon, such as VTE.
IBD is associated with a .3-fold increased risk of thromboem-
bolic disease with risk exceeding 15-fold during an IBD
ﬂare.
16,17,24 An Austrian prospective cohort study also suggested
that this risks extends into recurrent VTE with a HR of 2.5 (95%
CI, 1.4–4.2) in patients with IBD.
17 Interestingly, arterial throm-
botic events may also be increased in IBD. A large American
retrospective cohort study reported that patients with IBD had
a marked increase in risk of acute mesenteric ischemia (HR,
11.2; P , 0.001), although they did not ﬁnd an increased risk
in other arterial thrombotic events.
25 Overall, the impact of throm-
boembolic disease is signiﬁcant as the incidence of systemic
thromboembolic events has been reported as high as 7.7% in
some clinical studies.
26–28
The risk of thromboembolic phenomenon has also been
explored within CD and UC; however, the VTE study results are
not congruent. A Canadian population-based study of hospitalized
patients with IBD highlighted a slightly higher burden of deep
venous thrombosis and PE in CD. Speciﬁcally, in patients with CD,
the incidence rate ratio (IRR) for deep venous thrombosis was 4.7
(95% CI, 3.5–6.3) and for PE 2.9 (95% CI, 1.8–4.7), whereas in the
UC group, the IRR for deep venous thrombosis was 2.8 (95% CI,
2.1–3.7) and for PE 3.6 (95% CI, 2.5–5.2).
29 However, a large
American population-based study of hospitalized patients with
IBD suggests VTE was more prevalent among patients with UC
compared with CD (OR, 1.32; 95% CI, 1.17–1.48). Speciﬁcally,
U Ch a da nO Ro f1 . 8 4( 1 . 7 0 –2.01) for VTE, whereas CD had an
OR of 1.48 (1.35–1.62) compared with non-IBD patients.
30
Importantly, there is a paucity of data on mortality-
associated with VTE within IBD. Nguyen and Sam found that
VTE was associated with an increased risk of mortality in patients
with IBD after adjustment for demographic, hospital, and clinical
factors compared with non-VTE patients with IBD (aOR, 2.50;
95% CI, 1.83–2.43).
30 Additionally, they observed that after ad-
justing for confounding factors, patients with IBD with VTE had
a 2.1-fold increase in mortality compared with non-IBD patients
with VTE (95% CI, 1.6–2.9; P , 0.0001).
30 Between 1991 and
2000, Solem et al
31 observed a VTE-related mortality rate of 22%
after a median follow-up of 1.8 years in their IBD group. Inter-
estingly, this is in accordance with the reported mortality rate
reported in the same institution from 1970 to 1980.
26 The differ-
ences between VTE mortality in CD and UC have not been
extensively evaluated. Nguyen and Sam did suggest patients with
UC were more likely to have VTE-associated mortality. They
reported UC to have more VTE-associated morality (37.4 versus
9.9 cases per 1000 hospitalizations, P , 0.001) compared with
CD (17.0 versus 4.2 cases per 1000 hospitalizations, P ,
0.0001).
30 Overall, the exact increase in risk of death from throm-
boembolic disease is still unclear. Additional studies are required
to assess the precise burden of mortality of VTE in IBD and
delineate if CD or UC are particularly at risk.
CARDIOVASCULAR DISEASE-ASSOCIATED
MORTALITY IN IBD
Some chronic inﬂammatory diseases have been linked to
accelerated atherosclerosis, and preliminary studies have alluded
to endovascular dysfunction in IBD.
32 This relationship was fur-
ther explored in the context of IBD by Bernstein et al
9 who used
the Manitoba IBD administrative database to compare results with
a matched cohort. They found an increased risk for coronary
artery disease in patients with IBD (IRR 1.26; 95% CI, 1.11–
1.44); however, this risk was not signiﬁcant when IBD was strat-
iﬁed by IBD classiﬁcation: CD (1.50; 95% CI, 0.91–2.46) and UC
(1.11; 95% CI, 0.65–1.89).
9 Additionally, only patients with CD
displayed an increased risk for cerebrovascular disease (IRR,
1.32; 95% CI, 1.05–1.66). Although this study concluded that
patients with IBD were more likely to develop coronary artery
disease, the authors did not directly assess mortality associated
with coronary artery disease.
Cardiovascular (CV) mortality in IBD was assessed by
Dorn and Sandler
33 in a meta-analysis of 11 studies capturing
4532 patients with CD and 9533 patients with UC. The SMR
point estimates ranged from 0.7 to 1.5 for patients with CD and
0.6 to 1.1 for patients with UC; however, the meta-SMR for CD
was 1.0 (95% CI, 0.8–1.1) and the meta-SMR for UC was 0.9
(95% CI, 0.8–1.0).
33 Thus, these authors concluded that IBD is
not associated with increased CV-associated mortality.
33 This
result is in accordance with other meta-analyses that suggest that
the risk of CV-associated mortality was not increased in CD or
UC versus the general population.
3,34 Interestingly, a recent study
did observe a slightly elevated HR for CV-associated mortality in
CD (1.39; 95% CI, 1.28–1.51) and UC (1.20; 95% CI, 1.14–1.26),
and some reports have questioned if there may be a subgroup of
patients with IBD that are more susceptible.
6,35 Although a Dutch
study did not ﬁnd that patients with IBD had a signiﬁcantly
increased risk of CV-related mortality, they observed that individ-
uals with colonic CD were more likely to die of cardiovascular
disease (SMR, 3.5; 95% CI, 1.1–8.2).
35 Another study suggests
women older than 40 years with IBD were at increased risk for
myocardial infarction (HR, 1.6; P , 0.05) and women younger
than 40 years were shown to have an increased risk of stroke (HR,
2.4; P ¼ 0.04).
25 Although the IBD type, gender, and age differ-
ences are interesting, one must interpret the results with caution
because the role of smoking on the vascular burden may in fact be
the most important factor, and the overall risk of myocardial
infarction in patients with IBD was not signiﬁcantly increased.
25
Ultimately, the current body of literature does not support a strong
link to CV-associated mortality in IBD, and although subgroups
may be at risk, it remains unclear if this risk may be predomi-
nately driven by established environmental factors, such as
smoking.
INFECTION-ASSOCIATED MORTALITY IN IBD
Advances in IBD therapeutics have facilitated an increase in
use of agents that confer systemic immunosuppression and lead to
Inﬂamm Bowel Dis   Volume 20, Number 12, December 2014 IBD Cause-speciﬁc Mortality
www.ibdjournal.org | 2485increases in overall rates of infection.
36 Recent studies have high-
lighted the burden of infection-associated mortality in IBD. Jess
et al
6 reported the HR for infection-associated mortality was 3.23
(95% CI, 2.64–3.94) in CD and 2.21 (95% CI, 1.93–2.53) in UC.
Again, as noted above, mortality due to infection was dramatically
increased during the ﬁrst year after IBD diagnosis (UC: HR, 9.17;
95% CI, 7.19–11.69; CD: HR, 10.19; 95% CI, 6.88–15.11).
6
Ananthakrishnan and McGinley
37 reported that patients
with IBD with infection-related hospitalizations had signiﬁcantly
greater risk of mortality compared with those without (OR, 4.8;
95% CI, 3.67–5.23). Speciﬁcally, they noted the highest rates of
excess mortality was associated with sepsis (OR, 15.18; 95% CI,
12.39–16.61) and pneumonia (OR, 3.61; 95% CI, 2.92–4.47).
37
Enteric infections (OR, 2.58; 95% CI, 2.06–3.22) and urinary tract
infections (OR, 1.39; 1.13–1.72) also were associated with excess
mortality, whereas interestingly viral infections, abdominal
abscesses, candida, and postoperative infections did not seem to
carry any excess mortality.
37 The mortality burden of nosocomial
infections such as CDI and Methicillin-resistant Staphyloccoccus
aureus (MRSA) in IBD has been particularly signiﬁcant.
The emergence of CDI in IBD is well established with
a rise in CDI prevalence and recognition that patients with IBD
are vulnerable despite the absence of conventional risk fac-
tors.
18,38–40 This trend has been accompanied by a signiﬁcant CDI-
associated mortality. In the United States Nationwide Inpatient
Sample, CDI-associated mortality in the IBD cohort increased
dramatically from 1993 to 2003 with an overall in-hospital mor-
tality for patients with IBD with CDI of 5.7%.
18 The CDI-
associated mortality was higher in UC (7.7%) than in CD
(2.4%).
18 Also, the associated operative mortality for CDI was
higher in UC (25.7%) than CD (4.6%).
18 Another recent study
found that from 1998 to 2007, CDI in hospitalized patients with
IBD doubled (1.4%–2.9%), and there was an increase in absolute
CDI-associated mortality (5.9%–7.2%) leading to speculation
around the emergence of hypervirulent CDI strains as a possible
etiologic consideration.
41 Nguyen et al
42 also showed a near dou-
bling of the incidence of CDI in UC with a corresponding increase
in mortality risk compared with patients with UC alone (OR, 3.79;
95% CI, 2.84–5.06). More recently, a study suggests that CDI is
among the leading causes of infection-associated mortality in IBD
(OR, 3.23; 95% CI, 2.55–4.03).
37 Furthermore, Ananthakrishnan
et al
43 recently reported that host genetics may inﬂuence suscep-
tibility to CDI in IBD. They found that 6 documented IBD risk
polymorphisms were associated with an increased risk of CDI,
and 2 were inversely associated.
43 Overall, CDI has rapidly
become a major cause of morbidity and mortality in IBD, but
clinicians must be speciﬁcally aware that patients with UC may
be most vulnerable to CDI-associated adverse outcomes.
MRSA is a major cause of nosocomial infections world-
wide; however, there has been speculation that patients with IBD
may be at greater risk given risk factor proﬁles.
44,45 Nguyen et al,
44
compared the prevalence and in-hospital mortality of MRSA in-
fections among IBD, non-IBD GI, and general medical patients
using the United States Nationwide Inpatient Sample between
1998 and 2004. The authors concluded that patients with IBD were
at increased risk for MRSA infection compared with non-IBD GI
(aOR, 1.61; 95% CI, 1.33–1.96) and general medical inpatients
(aOR, 1.36; 95% CI, 1.11–1.66). Also, they found that patients
with IBD had an increased in-hospital mortality (aOR, 7.61;
P ¼ 0.001) compared with non-IBD GI (aOR, 3.20; 95% CI,
2.46–4.18) and general medical patients (aOR, 2.15; 95% CI,
1.57–2.93) with MRSA infections.
45 With the exponential global
rise of nosocomial infections such as MRSA and CDI, clinicians
must be aware of the susceptibility of nosocomial infections and
conventional infections in their vulnerable IBD patient population.
Infection-mediated macrophage activation syndrome
(MAS) in IBD has recently gained recognition. MAS is a clinical
syndrome characterized by fevers, peripheral blood cytopenias,
hepatosplenomegaly, and a constellation of laboratory abnormal-
ities including elevated serum ferritin, triglycerides, soluble
interleukin-2 receptor, in the context of decreased NK-cell
activity. A recent systematic review identiﬁed 50 cases of MAS
in IBD with a mortality rate of 30%.
46 Infection seemed to be
a main trigger particularly with associated cytomegalovirus or
Epstein–Bar virus infections, although bacterial infections seemed
to be a potential trigger in some cases. Given the high burden of
mortality with MAS in IBD, clinicians must be aware to facilitate
early diagnosis, especially in high-risk patients, such as those on
thiopurine therapy.
46
MEDICAL TREATMENT-ASSOCIATED MORTALITY
IN IBD
There has been growing concerns about treatment-related
mortality related to anti-tumor necrosis factor (TNF) therapy and
immunomodulator agents. Accordingly, a number of studies have
attempted to describe the mortality proﬁle of these core thera-
peutic interventions. In a study by Zabana et al
47 assessing 152
patients (121 CD, 24 UC, 7 indeterminate colitis) treated with
inﬂiximab, the mortality rate was 3% over a 9-year period. In
the larger TREAT Registry database of 6253 patients with CD,
3179 received inﬂiximab (5519 patient-years), and the mortality
rates were not different between those who received inﬂiximab
and patients with CD who did not (RR, 1.24; 95% CI, 0.73–
2.10).
48 A study pooled the primary safety data across 10 IBD
trials that compared inﬂiximab with placebo and found no
increase in malignancy or infections, including those classiﬁed
as serious.
49,50 More recently, a Dutch cohort of 469 patients with
CD on inﬂiximab reported a mortality of only 1.9% (0.39/100
patient-years).
51 Similarly, Colombel et al
52 reviewed the safety
data from 6 international clinical trials of patients with CD treated
with adalimumab and found that these patients had a decreased
SMR of 0.44 (95% CI, 0.12–1.12).
Although anti-TNF therapy seems to have a tolerable safety
proﬁle, there seems to be some discrepancy about immunomo-
dulators, such as 6-mercaptopurine, azathioprine, and methotrex-
ate. Lichtenstein et al suggest that in patients with UC, but not
CD, immunomodulator treatment is associated with a higher
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with placebo.
49,50 Additionally, they suggest that in patients with
CD, but not UC, immunomodulator treatment is associated with
a higher incidence of malignancy but again no increase in mor-
tality compared with placebo.
49,50 In contrast to this study, the
TREAT Registry data suggest immunomodulators are correlated
with a trend towards a decreased risk of death although this was
not statistically signiﬁcant (aOR, 0.731; 95% CI, 0.398–1.340).
48
Additionally, the TREAT Registry data highlighted that predni-
sone, and narcotic analgesics were independent risk factors for
serious infection (OR, 2.21; 95% CI, 0.64–1.54 and OR, 2.38;
95% CI, 1.56–3.63, respectively) and most importantly that pred-
nisone was the only factor associated with increased mortality risk
(OR, 2.10; 95% CI, 1.15–3.83).
48
Recently, Pasternak et al
53 reported on the use of azathio-
prine and the risk of cancer in patients with IBD. This large study
from Denmark found that azathioprine use was associated with an
overall increase in cancers (HR, 1.41; 95% CI, 1.15–1.74) but no
change in those previously exposed (HR, 1.02; 95% CI, 0.83–
1.25).
53 The only signiﬁcant increases were the risk of developing
lymphoid tissue cancers and urinary tract cancers but no signiﬁ-
cant increases in CRC or skin cancers in those taking or previ-
ously exposed to azathioprine.
53 The risk of skin cancer in IBD is
discussed further below. Overall, clinicians must be cautious with
their use of prednisone and narcotic in the treatment of IBD;
however, anti-TNF treatments seem to have a tolerable safety
proﬁle based on the current literature.
SURGERY-ASSOCIATED MORTALITY IN IBD
Postoperative mortality is an important factor in the
survival of patients with CD given the prevalence of surgery
among this patient population. It is estimated that up to 70% to
90% of patients with CD will require surgery at some point in
their disease course.
54 In the cohort study by Jess et al,
34 the 10-
year probability of intestinal resection during the ﬁrst decade after
diagnosis was 63% to 65% with no signiﬁcant change from cohort
1 (1962–1987) to cohort 2 (1991–1993). More recently, Kaplan’s
group reported in a systematic review and meta-analysis that sur-
gery rates for CD and UC have decreased over the last 6 deca-
des.
55 Risk of surgery 1, 5, and 10 years after diagnosis of CD was
16.3% (95% CI, 11.4%–23.2%), 33.3% (95% CI, 26.3%–42.1%),
and 46.6% (95% CI, 37.7%–57.7%), respectively.
55 The risk of
surgery 1, 5, and 10 years after diagnosis of UC was 4.9% (95%
CI, 3.8%–6.3%), 11.6% (95% CI, 9.3%–14.4%), and 15.6% (95%
CI, 12.5%–19.6%), respectively.
55
Muhe et al
56 reported on 155 patients who underwent intes-
tinal resection for CD, with an operative mortality rate of 8.4%
with 12 of 13 deaths related to perioperative sepsis. Subsequent
studies have reported signiﬁcantly lower mortality rates. In a study
of 282 patients who underwent a total of 331 intestinal resections,
the mortality rate was 1.2% with all cases attributed to perioper-
ative intra-abdominal sepsis.
57 A nationwide study in the United
States compared laparoscopic surgical approach versus traditional
open approaches in 396,911 patients admitted for CD, of whom
49,609 (12%) underwent surgery reported a low mortality rates in
both arms.
58 The mortality rate was 0.2% in the laparoscopic
group versus 0.9% in the open surgery group.
58 In a recent smaller
study comprising 124 patients who underwent laparoscopic ileo-
colonic resection, there were no surgical-related deaths reported.
59
Overall, advances in the ﬁeld of surgery have led to surgical
mortality rates falling signiﬁcantly in CD over the last 25 years.
Similarly, perioperative mortality in UC is an important
issue given the prevalence of surgical procedures among this
patient population. Approximately, 15% to 30% of patients with
UC will undergo colectomy at some point during the course of the
disease.
34,55,60 The 2 most common surgical procedures associated
with UC include total proctocolectomy with ileal pouch anal
anastomosis and total abdominal colectomy with ileostomy. Jess
et al
5 found that the probability of proctocolectomy in patients
with UC, during the ﬁrst decade after diagnosis, was similar in the
3 cohorts studied (1962–1987, 1991–1993, and 2003–2004) with
a 10-year probability of 24%. Similarly, Hefti et al
60 reported that
97 (17.3%) of 561 patients with UC underwent colectomy in
a study with a 21.4-year median follow-up period.
Kaplan et al
61 assessed postoperative mortality after colec-
tomy for UC in the United States using a Nationwide Inpatient
Sample Database of 7108 patients (1995–2005) and found an over-
all mortality rate of 2.3%.
61 Speciﬁcally, the mortality rate was the
lowest in those undergoing a pouch procedure (0.15%) and the
highest in patients with UC undergoing colectomy, ileostomy,
and rectal stump surgery (5.5%). Furthermore, in-hospital mortality
was higher in patients admitted emergently (aOR, 5.40; 95% CI,
3.48–8.40), in those older than 60 years of age (aOR, 8.70; 95% CI,
3.30–22.92), and in those with Medicaid healthcare insurance
(aOR, 4.29; 95% CI, 2.13–8.66). There was also an increased
mortality rate for patients with UC undergoing colectomy after
an emergent or urgent admission, with a mortality rate of 5.7%
compared with 0.7% in those admitted electively.
61 These rates
have also been observed in a more recent Danish cohort study.
62
They found that patients with IBD undergoing total emergency
colectomy had a 30-day mortality of 5.3% compared with 1% for
elective procedures and that patients with UC fared slightly better
than patients with CD in the context of emergency total colectomy
(5.3% versus 8.1% mortality, respectively).
62 Ikeuchi et al
63 re-
ported on surgical outcomes and mortality in a Japanese study of
1000 patients over a 24-year period. Ileal pouch anal anastomosis
was performed in 944 patients, with 79% of all cases performed
electively. They reported 20 postoperative deaths with 35% attrib-
utable to pneumonia, 25% due to sepsis, and 15% secondary to
advanced CRC as the major etiologies.
63 Overall, surgical mortality
is rare in UC but it still remains an important area of patient interest
given the prevalence of colectomy in this patient population.
64
LATE-ONSET IBD AND MORTALITY
Recent evidence has shown decreased survival and more
complicated course in late-onset IBD.
19,65–72 It is established that
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older than 60 years with 50% of those being diagnosed between 60
a n d7 0y e a r so fa g e .
71,73 Ananthakrishnan and Binion
19 found that
patients with IBD older than 65 years accounted for 25% of all
hospitalizations, with a higher proportion of admissions among
patients with UC (UC, 33.7% and CD, 20.3%). Furthermore, in-
hospital mortality was signiﬁcantly higher in the group aged 65 or
older (OR, 3.91; 95% CI, 2.5–6.11), even after adjusting for co-
morbidities. Generally, the disease course is more severe in elderly
patients with UC, and the in-hospital mortality rates are approxi-
mately 3 to 5 times higher in both UC and CD patients older than
65 years, when compared with younger groups.
72 Although CRC is
responsible for 15% of deaths in IBD, the difference in mortality
between early and late-onset IBD is not entirely accounted for by
CRC rates.
74 Overall, clinicians must be aware that late-onset IBD
carries it with a higher mortality particularly in UC and may require
a lower threshold for therapeutic escalation.
MALIGNANCY-ASSOCIATED MORTALITY IN IBD
Malignancy-associated mortality in IBD has developed into
an important area of IBD research both in terms of all-cause
malignancy and CRC-associated malignancy. Despite previous
perceptions, a recent study has suggested that patients with IBD
do not have a signiﬁcantly elevated risk of malignancy-associated
mortality compared with the general public.
6 They do suggest that
patients with CD may have a slightly increased risk (HR, 1.45;
95% CI, 1.35–1.56) compared with patients with UC (HR, 1.07;
95% CI, 1.02–1.12) but this was modest at the best.
6 They also
noted that the risk of dying of CRC has decreased (2000–2010
versus 1990–1999 and 1982–1989) with the largest decline seen
in the UC population 2000–2010 versus 1982–1989 (HR, 0.69;
95% CI, 0.49–0.98).
6 Interestingly, Romberg-Camps et al
35 re-
ported that mortality risk from all cancers was actually reduced
in IBD compared with the general population with a SMR of 0.5
for both UC (95% CI, 0.2–0.9) and CD (95% CI, 0.1–1.3)
although the rationale is elusive at present. This interesting obser-
vation was also found in a study from Winther et al
75 who re-
ported mortality from all cancers was signiﬁcantly lower than
expected in patients with UC (SMR, 0.70; 95% CI, 0.52–
0.93).
75 Additionally, a recent meta-analysis did not ﬁnd a signif-
icant increase in mortality risk from CRC in patients with CD
(SMR, 1.34; 95% CI, 0.54–3.33).
3 Recent cohort studies remain
divided on CRC-associated mortality in IBD.
76,77 Although pa-
tients with CD had an increased risk of dying from GI malignancy
(SMR, 4.7; 95% CI, 1.7–10), their relative risk of CRC was not
signiﬁcantly different from that expected (RR, 1.9), and the cumu-
lative risk of CRC was 2.4% after 25 years of CD.
78 Pancreatic
and small bowel tumors accounted for the majority of non-CRC
GI malignancy-related deaths.
78 Similarly, the meta-analysis by
Duricova et al
3 found an overall increased risk of death from all
cancers (SMR, 1.50; 95% CI, 1.18–1.92), but the main drivers of
this was pulmonary cancer (SMR, 2.72; 95% CI, 1.35–5.45) and
malignant melanoma (SMR, 10.0; 95% CI, 1.21–36.1).
Recent concerns about increased risk of skin cancers have
been raised in IBD. Bernstein’s group in Manitoba found that
patients with IBD had an increased risk of nonmelanoma skin
cancers (NMSC) (HR, 1.25; 95% CI, 1.09–1.43) and that the
use of thiopurines increased the risk of squamous cell carcinomas
(HR, 5.40; 95% CI, 2.00–14.56).
79 Similarly, a recent French
study by Peyrin-Biroulet showed that current (HR, 5.9; 95% CI,
2.1–16.4) and past (HR, 3.9; 95% CI, 1.3–12.1) thiopurines use
markedly increased the risk of NMSC in those with IBD.
80 Long
et al
81 studied a United States database with the largest cohort of
patients with IBD to date and also found an increased risk of
NMSC in those taking thiopurines (OR, 4.27; 95% CI, 3.08–
5.92). Although smaller studies failed to show a signiﬁcant
increase in NMSC in patients with IBD taking thiopurines (RR,
1.67; 95% CI, 0.86–3.21
53; OR, 0.99; 95% CI, 0.35–2.81
82; HR,
0.85; 95% CI, 0.51–1.41
83), the above larger more comprehensive
studies are strong evidence for increased risk.
The risk of melanoma has also been shown to be increased
in IBD
84 and has been found to be higher in CD (HR, 1.28; 95%
CI, 1.00–1.64), and the use of biologic therapies increased the risk
(OR, 1.88; 95% CI, 1.08–3.29).
85 Duricova et al
3 found a marked
increased risk of patients with CD dying from melanoma (SMR,
10.0; 95% CI, 1.21–36.1). However, a recent study with 49,735
patient-years of follow-up did not show an increased risk of mel-
anoma in patients with IBD compared with the general population
(SIR, 0.64; 95% CI, 0.17–1.63), and the risk was not increased
with thiopurines (SIR, 0; 95% CI, 0–3.11) or anti-TNF therapy.
86
Interestingly, in a large study of rheumatoid arthritis (29,555 pa-
tients), psoriasis (1298 patients), psoriatic arthritis (2498 patients),
and IBD (6357 patients), anti-TNF therapy was recently shown
not to increase the risk of any of the top 10 cancers or NMSC
compared with other therapies.
87 More studies are required to
further assess the risk patient with IBD on anti-TNF therapy
developing either NMSC or melanoma. It seems that patients with
IBD may have an increased risk of developing skin cancers, and
they should be counseled on protection against sun exposure and
consult with a dermatologist for screening on a regular basis,
especially those on thiopurines.
88
Singh et al
89 recently published a systematic review and
meta-analysis on the risk of melanoma in IBD. They assessed
12 studies that included 172,837 patients with IBD that included
179 IBD-melanoma cases and found IBD was associated with
a 37% increased risk of melanoma.
89 The risk was higher in
patients with CD (RR, 1.80; 95% CI, 1.17–2.75) versus UC
(RR, 1.23; 95% CI, 1.01–1.50), and the risk was higher before
introduction of biologic therapy in 1998 (7 studies; RR, 1.52;
95% CI, 1.02–2.25) but not in studies performed after 1998 (only
2 studies; RR, 1.08; 95% CI, 0.59–1.96).
89
The risk of CRC in IBD seems much more controversial in
the literature. Early studies suggested that those with UC had
signiﬁcantly increased risk of CRC than those with CD.
90–93 How-
ever, subsequent studies suggested that patients with CD with
colonic involvement also had an increase risk of CRC, potentially
more than the risk observed in UC.
94–97 These assertions have
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increased CRC-associated mortality.
5,75,78 Additionally, although
some cohorts suggest an elevated SIR for CRC, a recent meta-
analysis did not ﬁnd a signiﬁcant increase in mortality risk from
CRC in patients with CD (SMR, 1.34; 95% CI, 0.54–3.33).
3
Recent cohort studies seem to support this suggestion.
76 Although
patients with CD had an increased risk of dying from GI malig-
nancy (SMR, 4.7; 95% CI, 1.7–10), their relative risk of CRC was
not signiﬁcantly different from that expected (RR, 1.9) and the
cumulative risk of CRC was 2.4% after 25 years of CD.
78 Larsen
et al
98 compared 100 CRC patients with CD with 71, 438 CRC
patients without CD. They found that patients with CD developed
CRC at a younger age (57.7 versus 71.2 yr) and were more often
female (57% versus 51%).
98 Although the stage of CRC at diag-
nosis was similar between those with and without CD, those with
CD had reduced survival.
98 CRC is equally controversial in UC
patient population. Jess et al
34 also found no increased risk of CRC
in patients with UC in their Danish cohort, with only 14 patients
having developed CRC compared with expected 13 (SIR, 1.1; 95%
CI, 0.6–1.8). A more recent study by Jess et al
99 found the risk of
CRC among patients with UC was comparable with the general
population (RR, 1.07; CI, 0.95–1.21). Those with UC diagnosed in
childhood or adolescence, those with long duration of disease
(13 or more yr), and those with PSC were at increased risk.
99
Interestingly, they found that the risk of CRC in UC decreased
markedly from 1979 to 1988 (RR, 1.34; 95% CI, 1.13–1.58)
TABLE 1. Cause-speciﬁc Mortality in IBD Statements, Clinical Impact, and Risk Estimates
Statement
Clinical Impact (++:
Agree; 22:
Disagree) Highest Risk Estimate Lowest Risk Estimate
Overall Mortality
UC is associated with increased mortality + HR, 1.25 (95% CI, 1.22–1.28)
6 Pooled SMR, 1.1 (95% CI, 0.9–1.2)
5
CD is associated with increased mortality ++ HR, 1.73 (95% CI, 1.67–1.80)
6 SMR, 1.14 (95% CI, 0.84–1.49)
21
Thrombosis
Patients with IBD are more likely to die from
VTE then non-IBD patients
++ SMR, 4.0 (95% CI, 1.5–8.7)
5,a aOR, 2.1 (95% CI, 1.6–2.9)
30
Cardiovascular disease
Patients with CD are more likely to die from CV
disease than the general population
2 SMR, 3.5 (95% CI, 1.1–8.2)
35,b Meta-SMR 1.0 (95% CI, 0.8–1.1)
33
Patients with UC are more likely to die from CV
disease than the general population
22 SMR, 1.20 (95% CI, 1.14–1.26)
35 Meta-SMR, 0.9 (95% CI, 0.8–1.0)
33
CDI
Patients with UC are more likely to die from CDI
than non-IBD patients
++ OR, 3.79 (95% CI, 2.84–5.06)
42 OR, 3.23 (95% CI, 2.55–4.03)
37,c
Patients with CD are more likely to die from CDI
than non-IBD patients
+ OR, 3.23 (95% CI, 2.55–4.03)
37,c OR, 1.66 (95% CI, 0.75–3.66)
42
Anti-TNF therapy
Patients with CD are more likely to die on anti-
TNF therapy compared with patients with CD not
on anti-TNF treatment
22 RR, 1.24 (95% CI, 0.73–2.10)
48,d SMR, 0.44 (95% CI, 0.12–1.12)
52,e
Melanoma
Patients with IBD are at risk for melanoma +/2 SMR, 10 (95% CI, 1.21–36.1)
3,f SIR, 0.64 (95% CI, 0.17–1.63)
86,g
CRC
Patients with CD are more likely to die of CRC
compared with the general population
+/2 SMR, 3.12 (0.04–17.4)
100 Meta-SMR, 1.34 (0.54–3.33)
3
Patients with UC are more likely to die of CRC
compared with the general population
+/2 Meta-SMR, 1.9 (95% CI, 1.0–3.8)
5 SMR, 0.70 (95% CI, 0.52–0.93)
75
+, some evidence for agreement; ++, strong evidence for agreement; 2, some evidence for disagreement; 22, strong evidence for disagreement; +/2,c o n ﬂicting evidence.
aPulmonary embolism-associated mortality in UC.
bCV disease-associated mortality in colonic CD.
cCDI-associated mortality in hospitalized patients with IBD; no delineation between CD and UC.
dInﬂiximab-associated mortality in CD.
eAdalimumb-associated morality in CD.
fMelanoma-associated morality in CD.
gNo increased risk of melanoma in IBD population compared with general population, and in turn, melanoma-associated morality is a nonfactor.
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99 The
risk of CRC in CD was 0.85 (95% CI, 0.67–1.07) and did not
change over the above time periods.
99 The same group recently
completed a meta-analysis of population-based cohort studies
(based on review of meeting abstracts from 2006 to 2011) assess-
ing the risk of CRC in UC, and they found that UC increases the
risk of CRC (SIR, 2.4; 95% CI, 2.1–2.7).
4 Men with UC had
a greater risk of CRC (SIR, 2.6; 95% CI, 2.2–3.0) than women
(SIR, 1.9; 95% CI, 1.5–2.3).
4 They also found that young age at
diagnosis and extensive colitis increased the risk.
4
Overall, it seems from the body of literature that the rates of
IBD-associated CRC and associated mortality are falling, and
although some associated excess CRC related mortality may exist,
it is not as high as commonly perceived.
LIMITATIONS
There are several limitations that must be considered when
interpreting the data from this review. A major drawback of
epidemiology studies observing mortality is that many lack the
power necessary to detect a difference because of the low event
rate of death. Furthermore, there is a signiﬁcant amount of
heterogeneity in the characteristics of the study populations. Some
of the studies are population-based, whereas others were recruited
from hospitals, leading to selection bias. Population-based studies
have inherent challenges linked to coding terminology and
deﬁnitions including misclassiﬁcation bias. Determining the pre-
cise cause-speciﬁc mortality of nonspeciﬁc codes, such as GI
disease, is challenging and leads to speculation. Follow-up
periods established in the majority of studies are likely still too
short to allow for a better understanding of mortality in patients
with IBD. Importantly, many studies, particularly those determin-
ing SMR, did not control important confounders with smoking
being by far the most important. Smoking is known to increase
the risk of CD, while decreasing the risk of UC and is associated
with increased mortality from CV disease, pulmonary disorders,
and many malignancies. Given these limitations, one must be
cautious in the interpretation of mortality data in IBD.
CONCLUSIONS
Robust emerging literature is challenging previous data
regarding the magnitude of mortality in IBD. Although traditional
causes of death such as CRC may still be factor in IBD-associated
mortality, there are emerging threats that are likely to have a larger
impact on CD and UC patients. Thus, clinicians should be aware
of emerging new threats to patients with IBD and be able to
clearly convey the evidence-based risks to empower patients.
Overall, an evidence-based approach will allow early recognition
of mortality threats, which will translate into better patient
outcomes.
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